The traditional STING agonist development focuses on cyclic dinucleotides (CDNs), both natural and synthetic CDNs have been used for systemic administration.[53, 54] However, since STING is expressed in various cell types, including cancer and non‐cancer cells, this class of drugs lacks tumor specificity. This evidence concerns the gene STING1 and neoplasm.